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Abstract
Squamous cell carcinoma of the cervix, highly prevalent in the developing world, is often
metastatic and treatment resistant with no standard treatment protocol. Our laboratory pio-
neered the patient-derived orthotopic xenograft (PDOX) nude mouse model with the tech-
nique of surgical orthotopic implantation (SOI). Unlike subcutaneous transplant patient-
derived xenograft (PDX) models, PDOX models metastasize. Most importantly, the metas-
tasis pattern correlates to the patient. In the present report, we describe the development of
a PDOX model of HER-2-positive cervical cancer. Metastasis after SOI in nude mice includ-
ed peritoneal dissemination, liver metastasis, lung metastasis as well as lymph node metas-
tasis reflecting the metastatic pattern in the donor patient. Metastasis was detected in 4 of 6
nude mice with primary tumors. Primary tumors and metastases in the nude mice had histo-
logical structures similar to the original tumor and were stained by an anti-HER-2 antibody
in the same pattern as the patient’s cancer. The metastatic pattern, histology and HER-2
tumor expression of the patient were thus preserved in the PDOX model. In contrast, subcu-
taneous transplantation of the patient’s cervical tumors resulted in primary growth but
not metastasis.
Introduction
Cervical cancer is worldwide the second most common cancer in women with the majority of
squamous cell carcinoma (SCC) [1] resulting in 454,000 cases and 200,000 deaths per year in
2010. Frequent metastatic sites are the pelvic lymph nodes, para-aortic lymph nodes, lung,
extra-pelvic nodes, liver, and bones [2]. Approximately 11,000 new cases and 3,870 deaths
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occur for cervical carcinoma in the U.S. [3]. Stage and nodal metastasis are related to overall
survival [4]. Chemotherapy drugs used for cervical cancer include: paclitaxel, carboplatin, cis-
platinum, bleomycin, mitomycin-C, vincristine and irinotecan [5]. Retinoids and interferon, in
combination with cytotoxic chemotherapy, have been shown to be effective [6]. However,
there is no standard treatment for metastatic cervical cancer. Therefore, a patient-like mouse
model of cervical cancer could be very useful.
Our laboratory pioneered the patient-derived orthotopic xenograft (PDOX) nude mouse
model with the technique of surgical orthotopic implantation (SOI) [7–21]. Unlike subcutane-
ous-transplant patient-derived xenograft (PDX) models, PDOX models metastasize. Most im-
portantly, the metastasis pattern correlates to the patient.
Histologically intact human colon-cancer specimens derived surgically from patients were
implanted by SOI to the colon or cecum of nude mice. Extensive growth on the colon in 13 of
20 cases of implanted patient colon tumors was observed with subsequent regional, lymph-
node, and liver metastasis, as well as general abdominal carcinomatosis [7].
SOI of histologically intact pancreatic-cancer specimens to the nude-mouse pancreas, re-
sulted in a metastatic pattern that resembles the clinical pattern including local tumor growth,
extending to the stomach and duodenum, metastases to the liver and regional lymph nodes,
and distant metastases to the adrenal gland, diaphragm, and mediastinal lymph nodes. A 100%
take rate was demonstrated for 5 cases, of a total 17 mice transplanted, 15 supported tumor
growth. Immunohistochemical analysis of the transplanted human pancreatic tumors showed
a similar pattern of expression tumor-associated glycoprotein 72 and carcinoembryonic anti-
gen in the transplanted tumors and the original surgical biopsy [8].
Histologically-intact patient specimens of ovarian cancer were developed by SOI under the
capsule of the nude mouse ovary. The tumors grew locally with a subsequent patient-like meta-
static pattern, including the parietal peritoneum, colon, omentum, and ascites [10].
Histologically-intact patient breast tumor tissue was transplanted to the mammary fat
pad of nude mice by SOI where the tumor tissue grew extensively and metastasized to the
lung [11].
A patient-like metastatic model of human lung cancer constructed was developed with SOI
via thoracotomy in immunodeficient mice [9]. Tumors were transplanted into the left lung in
all these experimental animals. The left lung was used for tumor implantation for 2 reasons:
(1) the loss of lung function is smaller in the left lung than in right-lung during surgery. The
left-lung-operated animals survive the procedure better. (2) The left lung in mice has one
lobe, enabling tumors to readily develop after implantation [9]. When a poorly-differentiated
large-cell squamous-cell patient tumor 2268 was implanted to the left lung by SOI directly
from surgery, 5 out of 5 mice produced locally-grown tumors, in an average time of 61 days.
Opposite-lung metastases occurred, as well as lymph-node metastases. The primary tumors
and metastases in the mice maintained their large-cell-squamous-cell morphology. When
subcutaneously implanted tumors grew only locally in 2 of 4 animals and no metastases were
observed [9].
In a clinical correlative study of 20 cases of stomach cancer that grew in nude mice, 5 had
clinical liver metastases and all 5 cases resulted in liver metastases in the nude mice. Of the 20
cases, 6 had clinical peritoneal involvement of their tumor, and of these, 5 resulted in peritoneal
metastasis in the nude mice. There were statistically significant correlations for both liver me-
tastases and peritoneal involvement between patients and mice [12].
In the present report, we describe the development of a PDOX model of HER-2-positive
cervical cancer with a metastatic pattern similar to the patient donor.
Patient-Derived Orthotopic Xenograft (PDOX) Model of Cervical Cancer
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Materials and Methods
Animals
Female athymic (nu/nu) NCR nude mice (AntiCancer, Inc., San Diego, CA), 4–6 weeks old,
were used in this study. Mice were kept in a barrier facility under HEPA filtration. Mice were
fed with autoclaved laboratory rodent diet. All mouse surgical procedures and imaging were
performed with the animals anesthetized by intramuscular injection of a 0.02 ml solution of
50% ketamine, 38% xylazine, and 12% acepromazine maleate. All animal studies were con-
ducted with an AntiCancer Institutional Animal Care and Use Committee (IACUC)-protocol
specifically approved for this study and in accordance with the principals and procedures out-
lined in the National Institute of Health Guide for the Care and Use of Animals under Assur-
ance Number A3873–1.
Specimen collection
The patient provided written informed consent and the tumor specimen was procured under
the approval of the Institutional Review Board of University of California San Diego.
Orthotopic and subcutaneous implantation of patient derived xenograft
model of cervical cancer
Tumor tissues were obtained from the HER-2-positive cervical cancer patient at surgery and
cut into fragments (3-mm3) and transplanted subcutaneously in nude mice both subcutaneous-
ly and orthotopically.
For orthotopic transplantation, a small midline incision (6- to 10-mm) was made on the
lower abdomen of the mouse through the skin and peritoneum. The uterus was exposed
through this incision, and a single tumor fragment (3-mm3) was sutured to the cervix of the
uterus using 8–0 nylon surgical sutures (Ethilon; Ethicon Inc., NJ, USA). On completion, the
uterus was returned to the abdomen, and the incision was closed in one layer using 6–0 nylon
surgical sutures (Ethilon) [7, 13].
Tissue histology
Tumor tissue was removed with surrounding normal tissues at the time of resection. The tis-
sues were fixed in 10% formalin and embedded in paraffin before sectioning and staining. Tis-
sue sections (3 μm) were deparaffinized in xylene and rehydrated in an ethanol series.
Hematoxylin and eosin (H&E) staining was performed according to standard protocols. For
immunohistochemistry, sections (5 μm) were then treated for 30 min with hydrogen peroxide
(0.3%) to block endogenous peroxidase activity. The sections were subsequently washed with
PBS and unmasked in citrate antigen-unmasking solution (Mitsubishi Kagaku Iatron, Inc.,
Tokyo, Japan) in a water bath for 40 min at 98°C. After incubation with 10% normal goat
serum, the sections were incubated with anti-HER-2/ErbB2 (1:100; Cell Signaling Technology,
Inc., Danvers, MA, USA) at 4°C overnight. The binding of primary antibodies was detected
using anti-rabbit secondary antibodies and avidin/biotin/horseradish peroxidase complex
(DAKO Cytomation, Kyoto, Japan) for 30 min at room temperature. The labeled antigens were
visualized with the DAB kit (DAKO Cytomation). Finally, the sections were counterstained
with hematoxylin and examined using an BH-2 microscope (Olympus Corp., Tokyo, Japan)
equipped with a INFINITY1 2.0 megapixel CMOS digital camera (Lumenera Corporation, Ot-
tawa, Canada). All images were acquired using INFINITY ANALYZE software (Lumenera
Corporation) without post-acquisition processing.
Patient-Derived Orthotopic Xenograft (PDOX) Model of Cervical Cancer
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Statistical analysis
PASWStatistics 18.0 (SPSS, Inc) was used for statistical analyses. Correlations were examined
using the Fisher’s exact test. A p value< 0.05 was considered statistically significant for
all comparisons.
Results and Discussion
The PDOX, but not PDX, model of cervical cancer mimics the patient
metastatic pattern
After subcutaneous transplantation in nude mice of the patient cervical tumor, tumor growth
occurred in 7 of 10 mice but no metastasis occurred in any mouse (Table 1). Primary tumors
grew in 6 out of 8 nude mice after orthotopic implantation and metastasis grew in 4 mice
(Table 1). Metastasis in the nude mice included peritoneal dissemination, liver metastasis, lung
metastasis, as well as para-aortic lymph node metastasis) (Fig. 1) (Table 2). The patient had
metastasis in para-aortic lymph nodes, peritoneum, liver and messentary. Therefore, the
PDOX model mimicked the patients tumors metastatic pattern and the subcutaneous PDX
model had no metastasis. The growth rate of the primary tumor was rapid, doubling in 10–15
days during the 36-day growth period (Fig. 2). Examples of the sizes and shapes of the various
metastasis on various organs were as follows: A roundish liver metastasis (8.5 mm × 8.3 mm)
(Fig. 1E); two lung metastases (1.3 mm × 1.0 mm [oval]; 1.1 mm × 1.1 mm [round]) (Fig. 1F);
and two para-aortic lymph node metastases (4.0 mm × 2.3 mm [oval]; 4.6 mm × 2.1 mm
[oval]) (Fig. 1H). In future experiments, we will monitor the growth of metastasis from the cer-
vical carcinoma by intravital as well as non-invasive imaging [15–17].
Histology of the original tumor is preserved in the mouse
Sheet-like growth without gland formation and stromal tissue with fibroblastic proliferation,
which penetrated into the nests of carcinoma were observed in the H&E stained sections of the
original tumor (Fig. 3A). Oval- to spindle-shaped cancer cells with high nuclear/cytoplasmic
ratio were found in high magnification images (Fig. 3B). In the immunostained sections with
anti-HER-2 antibody, the membrane and the cytoplasm of cancer cells were strongly stained
but no staining was found in the stromal tissue (Fig. 3C and 3D). All mouse-grown cervical
cancer patient tumor including the metastatic tumors had histological structures similar to the
original tumor and were stained by anti-human HER-2 antibody (Fig. 3E-3H), suggesting that
the model recapitulates the biological behaviors of the original tumor.
A PDOX model of HER-2-positive metastatic cervical cancer, which shows metastatic be-
havior throughout the mouse body including liver, lymph-nodes, lung, peritoneum, has not
been previously reported. More important, the metastasis pattern of the PDOX tumor mim-
icked that of the patient. We further demonstrated that the mouse-grown tumors recapitulate
the character of the original patient tumor by examining the expression status of HER-2. In the
present study, we demonstrate that primary tumors and metastasis grown in the mouse were
stained by anti-HER-2 antibody and recapitulated histological structures of the original tumor
Table 1. Comparison of primary tumor and metastasis occurrence in subcutaneous (PDX) and orthotopic (PDOX) models.
Model No. of mice implanted Tumor-take rate (%) Metastasis (%)
Nude mouse subcutaneous (PDX) 10 7 / 10 (70) 0 (0)
Nude mouse orthotopic (PDOX) 8 6 / 8 (75) 4 / 8 (50)
doi:10.1371/journal.pone.0117417.t001
Patient-Derived Orthotopic Xenograft (PDOX) Model of Cervical Cancer
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Fig 1. Metastasis in the cervical cancer PDOXmodel in nudemice. (A) Whole body imaging of the nude
mouse orthotopically transplanted the patient’s cervical cancer specimen three monthly previously. The
abdomen became distended with the tumor. (B) Images from laparotomy. The large primary tumor was fused
with peritoneally-disseminated tumors (yellow arrows). Engorged nodule in the liver is a liver metastasis (blue
arrows). Peritoneal dissemination was detected in the subphrenic space (white arrows). (C) Image
thoracotomy. Two white nodules were detected in the lower lobe of the right lung (black arrows). (D) Excised
specimens of primary tumor. The primary tumor was fused with peritoneally-disseminated tumors. (E)
Excised liver metastasis specimens. Upper right inset shows the cut surface of tumor. (F) Excised lung
metastasis specimens. Two white nodules were detected in the lower lobe of right lung (black arrows). (G and
H) Images of a nude mouse developing para-aortic lymph node metastasis. The primary tumor engulfed the
bladder (yellow arrows). After removal of the primary tumor, para-aortic lymph node metastases could be
detected (black arrows). SP: spleen, STM: stomach, SMI: small intestine, Eso: esophagus, KD: kidney. Scale
bars, 10 mm.
doi:10.1371/journal.pone.0117417.g001
Patient-Derived Orthotopic Xenograft (PDOX) Model of Cervical Cancer
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(Fig. 2). The incidence of HER-2 positivity in cervical cancer was reported from 1% to 21%
[22], and overexpression of HER-2 has been associated with more advanced stages and a worse
prognosis [23, 24].
The PDOX model of cervical cancer described in the present report could have multiple
uses: For example, we have recently used a PDOX nude mouse model of pancreatic cancer and
colon cancer to develop techniques for fluorescence-guided surgery [25–27]. A pancreatic can-
cer PDOX nude mouse model was used to evaluate the efficacy of the tumor-targeting Salmo-
nella typhimurium (S. typhimurium) A1-R strain we are developing. S. typhimurium A1-R
significantly reduced tumor growth compared to the untreated control [28].
S. typhimurium A1-R, in combination with anti-vascular endothelial growth factor (VEGF)
therapy using bevacizumab (BEV), was active in the pancreatic cancer PDOX [29].
We also previously demonstrated zoledronic acid (ZA) is active on pancreatic cancer in a
PDOX model on primary and metastatic growth [30].
Thus, the patient-mimicking PDOX model of cervical cancer described in the present report
presents many opportunities for discovery of novel effective therapeutics for this currently
treatment-resistant disease. After discovery of more effective therapeutics, the PDOX model of
Table 2. Sites of metastasis in PDOX model and the patient.
Mouse Sites of metastasis
Mouse 1 Peritoneum, Liver, Lung
Mouse 2 Peritoneum, Mesentery
Mouse 3 Peritoneum
Mouse 4 Para-aortic lymph nodes, Mesentery
Patient Para-aortic lymph nodes, Peritoneum, Mesentery, Liver
doi:10.1371/journal.pone.0117417.t002
Fig 2. Growth rate of primary tumor. The tumor diameter was measured with calipers and volume calculated using the following formula: 4/3π●(d/2)2●D/2.
doi:10.1371/journal.pone.0117417.g002
Patient-Derived Orthotopic Xenograft (PDOX) Model of Cervical Cancer
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cervical cancer can be more useful for individualized patient therapy. The present report also
emphasizes the critical advantages of the PDOX model over the subcutaneous PDX model
[31–34].
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